Bivalirudin and Desmopressin Market Trends
Growth Drivers
- Rising Percutaneous Coronary Interventions (PCI) Procedures Among Heart Patients - According to the American Heart Association, the number of percutaneous coronary interventions (PCI) in the United States reaches more than 600 000 each year, resulting in over USD 12 billion in healthcare expenditures. Percutaneous coronary intervention is a non-surgical procedure that involves placing a small stent into narrowed blood vessels in the heart caused by atherosclerosis using a thin flexible tube. Percutaneous Coronary Intervention (PCI) is becoming increasingly popular to treat acute coronary syndrome. With the use of anticoagulation therapy increasing during PCI, the risk of thrombotic complications is being reduced. This factor is expected to enlarge global bivalirudin and desmopressin market size during the forecast period.
- Growing Patients of Cancer Worldwide – According to the World Health Organization, cancer is the leading cause of death worldwide. In 2020, nearly 10 million people died from this disease. There are about 400 000 cases of cancer in children each year.
- Increasing Number Of Elderly People Suffering From Nocturia- In a study it was found that about 65% of men and 73% of women over 40 admitted getting up to use the bathroom at least once per night. It is estimated that approximately 50% of men who are 70 years old wake up at least twice a night to relieve themselves. The number of elderly people who suffer from nocturia may reach up to 80%.
- Higher Prevalence of Coronary Artery Disease Worldwide - According to the Centers for disease control and prevention in 2020, 382,820 people died from coronary heart disease. The incidence of CAD among adults aged 20 and over is about 7.2%. The proportion of deaths from CAD among adults younger than 65 years old is about 2 in 10.
- Globally Rising Patients of Diabetes - According to International Diabetes Federation, Diabetes affected approximately 537 million adults (20-79 years) in 2021. Diabetes is expected to affect 643 million people by 2030 and 783 million by 2045. A common sign and symptom of diabetes is excessive thirst and urination. People who suffer from diabetes urinate four to seven times a day on average. Thus, rising cases of diabetes worldwide are estimated to propel the demand for desmopressin during the forecast period.
Challenges
- High Cost Associated with the Bivalirudin Drug
- Health Concerns Such as Bleeding, Difficulty Breathing, and Sudden Numbness
- Unawareness Among People Regarding Less Medical Treatments
Bivalirudin and Desmopressin Market: Key Insights
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.1% |
|
Regional Scope |
|
